RU2012134974A - Стабилизированное соединение гормона роста - Google Patents
Стабилизированное соединение гормона роста Download PDFInfo
- Publication number
- RU2012134974A RU2012134974A RU2012134974/10A RU2012134974A RU2012134974A RU 2012134974 A RU2012134974 A RU 2012134974A RU 2012134974/10 A RU2012134974/10 A RU 2012134974/10A RU 2012134974 A RU2012134974 A RU 2012134974A RU 2012134974 A RU2012134974 A RU 2012134974A
- Authority
- RU
- Russia
- Prior art keywords
- growth hormone
- hormone compound
- compound according
- seq
- additional
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 37
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract 33
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract 33
- 239000000122 growth hormone Substances 0.000 title claims abstract 33
- 230000035772 mutation Effects 0.000 claims abstract 12
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract 10
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract 10
- 239000000854 Human Growth Hormone Substances 0.000 claims abstract 10
- 102200153349 rs104894823 Human genes 0.000 claims abstract 8
- 102220078630 rs61735992 Human genes 0.000 claims abstract 5
- 102200070479 rs28933693 Human genes 0.000 claims abstract 4
- 102220259718 rs34120878 Human genes 0.000 claims abstract 4
- 102200083530 rs34382405 Human genes 0.000 claims abstract 4
- 102200124873 rs58730926 Human genes 0.000 claims abstract 3
- 108091005804 Peptidases Proteins 0.000 claims abstract 2
- 239000004365 Protease Substances 0.000 claims abstract 2
- 235000018417 cysteine Nutrition 0.000 claims abstract 2
- 150000001945 cysteines Chemical class 0.000 claims abstract 2
- 102200016458 rs104894274 Human genes 0.000 claims abstract 2
- 102220257167 rs1553408119 Human genes 0.000 claims abstract 2
- 102220047964 rs587783194 Human genes 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 3
- 102220573434 Fibroblast growth factor 22_D14C_mutation Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102220005446 rs34743106 Human genes 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 102220471848 Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1_F14C_mutation Human genes 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 102220062540 rs372619120 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29730510P | 2010-01-22 | 2010-01-22 | |
| US61/297,305 | 2010-01-22 | ||
| EP10151405 | 2010-01-22 | ||
| EP10151405.7 | 2010-01-22 | ||
| CNPCT/CN2010/001120 | 2010-07-23 | ||
| CN2010001120 | 2010-07-23 | ||
| US37860210P | 2010-08-31 | 2010-08-31 | |
| US61/378,602 | 2010-08-31 | ||
| PCT/EP2011/050909 WO2011089250A2 (en) | 2010-01-22 | 2011-01-24 | Stable growth hormone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012134974A true RU2012134974A (ru) | 2014-02-27 |
Family
ID=44166478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134974/10A RU2012134974A (ru) | 2010-01-22 | 2011-01-24 | Стабилизированное соединение гормона роста |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9211342B2 (enExample) |
| EP (1) | EP2525833A2 (enExample) |
| JP (1) | JP5980689B2 (enExample) |
| AU (1) | AU2011208620B2 (enExample) |
| BR (1) | BR112012018162A2 (enExample) |
| CA (1) | CA2787895A1 (enExample) |
| IL (1) | IL220648A0 (enExample) |
| MX (1) | MX338357B (enExample) |
| RU (1) | RU2012134974A (enExample) |
| WO (1) | WO2011089250A2 (enExample) |
| ZA (1) | ZA201205385B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX345736B (es) | 2010-01-22 | 2017-02-14 | Novo Nordisk Healthcare Ag | Hormonas de crecimiento con eficacia in vivo prolongada. |
| US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
| CN103269720A (zh) * | 2010-07-22 | 2013-08-28 | 诺沃—诺迪斯克保健股份有限公司 | 生长激素缀合物 |
| WO2014139994A1 (en) | 2013-03-11 | 2014-09-18 | Novo Nordisk Health Care Ag | Growth hormone compounds |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| WO2015036553A1 (en) | 2013-09-16 | 2015-03-19 | Novo Nordisk Health Care Ag | Thiol functionalized polymers |
| EP3079722B1 (en) | 2013-12-13 | 2021-03-24 | Novo Nordisk Health Care AG | Method for thioether conjugation of proteins |
| US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| AU2016326392B2 (en) | 2015-09-22 | 2021-02-11 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
| KR20180003677A (ko) * | 2016-06-30 | 2018-01-10 | 주식회사 크레아플래닛 | 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504099D0 (en) | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| ATE198353T1 (de) | 1988-08-24 | 2001-01-15 | American Cyanamid Co | Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung |
| ATE189526T1 (de) | 1988-10-28 | 2000-02-15 | Genentech Inc | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| JPH04504246A (ja) | 1989-03-20 | 1992-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン刺激ホルモン |
| US5101018A (en) | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| WO1991011457A1 (en) | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5951972A (en) | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| DK220890D0 (da) | 1990-09-14 | 1990-09-14 | Ole Buchardt | Fremgangsmaade til fremstilling af c-terminalt amiderede peptider |
| JP3267293B2 (ja) * | 1990-12-03 | 2002-03-18 | ジェネンテク，インコーポレイテッド | 改変された結合性を有する変異タンパク質の豊富化法 |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| IT1251895B (it) * | 1991-09-27 | 1995-05-26 | Eniricerche Spa | Mutanti dell'ormone della crescita umano e loro impiego |
| DE69333718T2 (de) | 1992-01-14 | 2005-12-01 | Ajinomoto Co., Inc. | Gen, das für eine Fisch-Transglutaminase kodiert |
| ES2153385T5 (es) | 1992-07-31 | 2008-09-01 | Genentech, Inc. | Composicion acuosa a base de hormona del crecimiento humana. |
| ZA936811B (en) | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| WO1995020662A1 (en) | 1994-01-28 | 1995-08-03 | Ajinomoto Co., Inc. | Transglutaminase originating in japanese oyster |
| JP3720363B2 (ja) | 1994-08-26 | 2005-11-24 | ノボザイムス アクティーゼルスカブ | 微生物のトランスグルタミナーゼ、それらの産生及び使用 |
| US6010871A (en) | 1994-09-29 | 2000-01-04 | Ajinomoto Co., Inc. | Modification of peptide and protein |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| ATE248219T1 (de) | 1995-01-19 | 2003-09-15 | Novozymes As | Transglutaminasen aus oomyzeten |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE851925T1 (de) | 1995-09-21 | 2003-08-14 | Genentech Inc., San Francisco | Varianten des menschlichen wachstumshormons |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| WO1998008872A1 (en) | 1996-08-30 | 1998-03-05 | Novo Nordisk A/S | Glp-2 derivatives |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| EP0950665A4 (en) | 1996-09-26 | 2004-05-06 | Ajinomoto Kk | PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM |
| US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
| JPH1156378A (ja) * | 1997-06-11 | 1999-03-02 | Nippon Chem Res Kk | 変異型ヒト成長ホルモンとその用途 |
| PT996629E (pt) | 1997-06-25 | 2006-12-29 | Applied Research Systems | Análogos de hormonas glicoproteicas reticulados com ligações dissulfito, sua preparação e utilização |
| EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| JPH1192499A (ja) * | 1997-09-22 | 1999-04-06 | Sumitomo Pharmaceut Co Ltd | ヒト成長ホルモン変異体 |
| US6136536A (en) | 1997-10-29 | 2000-10-24 | Genetics Institute, Inc. | Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins |
| AU2610799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates |
| JP2002504527A (ja) | 1998-02-27 | 2002-02-12 | ノボ ノルディスク アクティーゼルスカブ | 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体 |
| WO1999043705A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| DE69942307D1 (de) | 1998-02-27 | 2010-06-10 | Novo Nordisk As | N-terminal veränderte glp-1 abkömmlinge |
| US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| US6358705B1 (en) | 1998-07-16 | 2002-03-19 | Novo Nordisk A/S | Method of making proteins in transformed yeast cells |
| SG125915A1 (en) | 1998-12-07 | 2006-10-30 | Sod Conseils Rech Applic | Analogues of glp-1 |
| US6329336B1 (en) | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| WO2001004287A1 (en) | 1999-07-07 | 2001-01-18 | Maxygen Aps | A method for preparing modified polypeptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| EP1250126A2 (en) | 2000-01-11 | 2002-10-23 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| NZ522847A (en) * | 2000-05-16 | 2004-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| AU2002219021A1 (en) | 2001-01-11 | 2002-07-24 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
| EP1423136A4 (en) | 2001-08-10 | 2007-07-25 | Epix Pharm Inc | POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| JP2005518786A (ja) | 2001-11-12 | 2005-06-30 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | ヒトにおける成長ホルモン変異とその用途 |
| WO2003044056A2 (en) | 2001-11-20 | 2003-05-30 | Pharmacia Corporation | Chemically-modified human growth hormone conjugates |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| FR2836382B1 (fr) | 2002-02-28 | 2004-08-13 | Biomerieux Sa | Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic |
| EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| US20050164925A1 (en) | 2002-04-10 | 2005-07-28 | Joseph Anthony Jakubowski And Thurman Dwight Mc Kinney | Treatment of gastroparesis |
| PL373728A1 (en) | 2002-04-30 | 2005-09-05 | Maxygen Holdings Ltd. | Factor vii or viia polypeptide variants |
| US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
| EP2067483A1 (en) | 2003-02-19 | 2009-06-10 | Ipsen Pharma | Analogues of GLP-1 |
| JP2007524584A (ja) | 2003-05-09 | 2007-08-30 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療に使用するペプチド |
| EP1654004A2 (en) | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| CN100580087C (zh) | 2003-10-10 | 2010-01-13 | 诺和诺德医疗保健公司 | 肽的缀合 |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| ATE461217T1 (de) | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
| CA2552043A1 (en) | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| BRPI0507159A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos |
| UA89781C2 (uk) | 2004-04-07 | 2010-03-10 | Арес Трейдінг С.А. | Рідкий склад гормона росту |
| US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| MXPA06015049A (es) | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
| US20090176967A1 (en) | 2004-08-02 | 2009-07-09 | Novo Nordisk Healthcare A/G | Conjugation of FVII |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| US7998930B2 (en) * | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| CA2594561C (en) | 2004-12-22 | 2014-12-23 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2007011307A (es) | 2005-03-18 | 2007-10-08 | Novo Nordisk As | Compuestos de glp-1 extendidos. |
| EP1863537A2 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| WO2007020291A1 (en) | 2005-08-18 | 2007-02-22 | Novo Nordisk Health Care Ag | Improving transglutaminase substrate specificity |
| US8293708B2 (en) | 2005-08-30 | 2012-10-23 | Novo Nordisk Health Care A/G | Liquid formulations N-terminal serine of pegylated growth hormone |
| CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
| CN101384711A (zh) * | 2006-01-19 | 2009-03-11 | Ambrx公司 | 具有经调节的免疫原性的非天然氨基酸多肽 |
| EP1986694B1 (en) | 2006-02-14 | 2015-06-10 | Novo Nordisk Health Care AG | Coupling of polypeptides at the c-terminus |
| WO2008003750A2 (en) | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
| ES2745411T3 (es) | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
| JP2010500886A (ja) | 2006-08-18 | 2010-01-14 | ノボ ノルディスク ヘルス ケア アーゲー | 改善された特異性を有するトランスグルタミナーゼ変異体 |
| US20080095837A1 (en) | 2006-08-31 | 2008-04-24 | Emisphere Technologies, Inc. | Human growth hormone formulations |
| PL2059260T3 (pl) | 2006-08-31 | 2014-03-31 | Novartis Ag | Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego |
| US8383852B2 (en) | 2007-02-16 | 2013-02-26 | Emisphere Technologies, Inc. | Compounds having a cyclic moiety and compositions for delivering active agents |
| WO2008112836A2 (en) | 2007-03-15 | 2008-09-18 | Novartis Ag | Pharmaceutical composition comprising human growth hormon |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| EP2324056A1 (en) | 2008-09-09 | 2011-05-25 | Novo Nordisk Health Care AG | Growth hormone conjugate with increased stability |
| US8637647B2 (en) | 2008-09-12 | 2014-01-28 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| CN102292349B (zh) | 2009-01-22 | 2016-04-13 | 诺沃—诺迪斯克保健股份有限公司 | 稳定的生长激素化合物 |
| CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
| CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
| US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
| MX345736B (es) | 2010-01-22 | 2017-02-14 | Novo Nordisk Healthcare Ag | Hormonas de crecimiento con eficacia in vivo prolongada. |
| WO2011101261A2 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Purification method |
-
2011
- 2011-01-24 US US13/574,128 patent/US9211342B2/en not_active Expired - Fee Related
- 2011-01-24 RU RU2012134974/10A patent/RU2012134974A/ru unknown
- 2011-01-24 BR BR112012018162A patent/BR112012018162A2/pt not_active IP Right Cessation
- 2011-01-24 EP EP11703842A patent/EP2525833A2/en not_active Withdrawn
- 2011-01-24 CA CA2787895A patent/CA2787895A1/en not_active Withdrawn
- 2011-01-24 JP JP2012549376A patent/JP5980689B2/ja not_active Expired - Fee Related
- 2011-01-24 AU AU2011208620A patent/AU2011208620B2/en not_active Ceased
- 2011-01-24 MX MX2012007999A patent/MX338357B/es active IP Right Grant
- 2011-01-24 WO PCT/EP2011/050909 patent/WO2011089250A2/en not_active Ceased
-
2012
- 2012-06-26 IL IL220648A patent/IL220648A0/en unknown
- 2012-07-18 ZA ZA2012/05385A patent/ZA201205385B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL220648A0 (en) | 2012-08-30 |
| WO2011089250A3 (en) | 2011-10-13 |
| WO2011089250A2 (en) | 2011-07-28 |
| ZA201205385B (en) | 2013-04-24 |
| US9211342B2 (en) | 2015-12-15 |
| JP5980689B2 (ja) | 2016-08-31 |
| EP2525833A2 (en) | 2012-11-28 |
| AU2011208620B2 (en) | 2015-04-16 |
| CA2787895A1 (en) | 2011-07-28 |
| JP2013518037A (ja) | 2013-05-20 |
| AU2011208620A1 (en) | 2012-07-19 |
| BR112012018162A2 (pt) | 2017-10-03 |
| MX2012007999A (es) | 2012-08-03 |
| US20130040883A1 (en) | 2013-02-14 |
| MX338357B (es) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012134974A (ru) | Стабилизированное соединение гормона роста | |
| JP2013518037A5 (enExample) | ||
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| PE20010740A1 (es) | Aminoacidos biciclicos como agentes farmaceuticos | |
| IL277215B1 (en) | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| IN2014KN02752A (enExample) | ||
| MX377317B (es) | Compuestos de hormona de crecimiento humana recombinante unidos a peg. | |
| RU2008136324A (ru) | Желудочно-кишечный пролиферативный фактор и его применения | |
| EA200701956A1 (ru) | Лекарственные формы октреотида с контролируемым высвобождением | |
| RU2011133926A (ru) | Стабилизированные гормоны роста | |
| PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta | |
| RU2012122162A (ru) | Гликолизированная форма аналога антигенного glp-1 | |
| NZ599604A (en) | Synthetic myostatin peptide antagonists | |
| RU2013147739A (ru) | Фармацевтическая композиция | |
| PH12022550392A1 (en) | Compositions and methods of treating vascular diseases | |
| JP2012515748A5 (enExample) | ||
| RU2013126888A (ru) | ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100 | |
| SI1594885T1 (sl) | Zdravilo za inhibiranje rasti tumorjev | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| DOP2005000091A (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il) amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico | |
| RU2014114790A (ru) | Новый вариант альфа-1-антитрипсина, способ его получения и применения | |
| MX2015014704A (es) | Compuestos, composiciones y métodos para el tratamiento de las enfermedades a través de la inhibición de la actividad del tgf-b. | |
| MX2024005654A (es) | Análogos de la proteína de fusión de la relaxina-2 y métodos de usos de los mismos. | |
| JP2014512369A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant | ||
| FA91 | Application withdrawn (on applicant's request) |
Effective date: 20160614 |